Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment

被引：4

作者：

Menges, Dominik ^{[1
]}

Piatti, Michela C. ^{[1
]}

Omlin, Aurelius ^{[2
,3
]}

Cathomas, Richard ^{[4
]}

Benamran, Daniel ^{[5
]}

Fischer, Stefanie ^{[2
]}

Iselin, Christophe ^{[5
]}

Kung, Marc ^{[6
]}

Lorch, Anja ^{[7
]}

Prause, Lukas ^{[8
]}

Rothermundt, Christian ^{[2
]}

Stern, Alix O'Meara ^{[9
]}

Zihler, Deborah ^{[10
]}

Lippuner, Max ^{[11
]}

Braun, Julia ^{[1
]}

Cerny, Thomas ^{[12
,13
]}

Puhan, Milo A. ^{[1
]}

机构：

[1] Univ Zurich, Epidemiol Biostat & Prevent Inst, Hirschengraben 84, CH-8001 Zurich, Switzerland

[2] Kantonsspital St Gallen, Dept Med Oncol & Hematol, St Gallen, Switzerland

[3] Onkozentrum Zurich, Zurich, Switzerland

[4] Kantonsspital Graubunden, Div Oncol Hematol, Chur, Switzerland

[5] Hop Univ Geneve, Dept Urol, Geneva, Switzerland

[6] Hop Cantonal Fribourg, Dept Oncol, Fribourg, Switzerland

[7] Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland

[8] Kantonsspital Aarau, Dept Urol, Aarau, Switzerland

[9] Reseau Hosp Neuchatelois, Dept Oncol, Neuchatel, Switzerland

[10] Kantonsspital Aarau, Dept Oncol Hematol & Transfus Med, Aarau, Switzerland

[11] Europa Uomo Switzerland, Ehrendingen, Switzerland

[12] Fdn Board, Canc Res Switzerland, Bern, Switzerland

[13] Swissmedic, Human Med Expert Comm, Bern, Switzerland

来源：

EUROPEAN UROLOGY OPEN SCIENCE | 2023年 / 51卷

关键词：

Adverse effects; Benefit; Benefit-harm assessment; Discrete choice experiment; Harm; Metastasis; Patient-centered care; Patient preferences; Prostate cancer; Survival; Treatment; LIFE-CYCLE; INFORM; THERAPY; DESIGNS;

D O I：

10.1016/j.euros.2023.03.001

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Patient preferences for treatment outcomes are important to guide decision-making in clinical practice, but little is known about the preferences of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Objective: To evaluate patient preferences regarding the attributed benefits and harms of systemic treatments for mHSPC and preference heterogeneity between individuals and specific subgroups. Design, setting, and participants: We conducted an online discrete choice experiment (DCE) preference survey among 77 patients with metastatic prostate cancer (mPC) and 311 men from the general population in Switzerland between November 2021 and August 2022. Outcome measurements and statistical analysis: We evaluated preferences and preference heterogeneity related to survival benefits and treatment-related adverse effects using mixed multinomial logit models and estimated the maximum survival time participants were willing to trade to avert specific adverse effects. We further assessed characteristics associated with different preference patterns via subgroup and latent class analyses. Results and limitations: Patients with mPC showed an overall stronger preference for survival benefits in comparison to men from the general population (p = 0.004), with substantial preference heterogeneity between individuals within the two

引用

页码：26 / 38

页数：13

共 50 条

[21] Patient Preferences in Subglottic Stenosis Treatment: A Discrete Choice Experiment
Naunheim, Matthew R.
Naunheim, Margaret L.
Rathi, Vinay K.
Franco, Ramon A.
Shrime, Mark G.
Song, Phillip C.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2018, 158 (03) : 520 - 526
[22] CHRONIC PAIN: PATIENT TREATMENT PREFERENCES - A DISCRETE CHOICE EXPERIMENT
Muehlbacher, A.
Ezemieks, J.
Nuebling, M.
VALUE IN HEALTH, 2011, 14 (07) : A417 - A418
[23] Patient preferences for treatment of psoriasis with biologics: a discrete choice experiment
Kromer, C.
Schaarschmidt, M. -L.
Schmieder, A.
Herr, R.
Goerdt, S.
Peitsch, W. K.
BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E125 - E125
[24] Patient Preferences for Cholesterol Treatment Options: A Discrete Choice Experiment
Lewey, Jennifer
Choudhry, Niteesh K.
Gagne, Joshua J.
Avorn, Jerry
Najafzadeh, Mehdi
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 157 - 157
[25] Patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment
Schaarschmidt, M. L.
Kromer, C.
Herr, R.
Schmieder, A.
Goerdt, S.
Peitsch, W. K.
EXPERIMENTAL DERMATOLOGY, 2015, 24 (03) : E18 - E18
[26] Patient preferences for the treatment of chronic cough: a discrete choice experiment
Swaminathan, Aparna C.
Yang, Jui-Chen
Ding, Helen
Grover, Kiran
Coles, Theresa
Schelfhout, Jonathan
Johnson, F. Reed
BMJ OPEN RESPIRATORY RESEARCH, 2024, 11 (01)
[27] Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment
Kromer, Christian
Schaarschmidt, Marthe-Lisa
Schmieder, Astrid
Herr, Raphael
Goerdt, Sergij
Peitsch, Wiebke K.
PLOS ONE, 2015, 10 (06):
[28] Patient Preferences for Provider Choice: A Discrete Choice Experiment
van den Broek-Altenburg, Eline M.
Atherly, Adam J.
AMERICAN JOURNAL OF MANAGED CARE, 2020, 26 (07): : E219 - +
[29] Patient Preferences for Provider Choice: A Discrete Choice Experiment
van den Broek-Altenburg, Eline
Atherly, Adam
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2020, 13 (01): : 142 - 142
[30] Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful Benefits
Richardson, Daniel R.
Crossnohere, Norah L.
Seo, Jaein
Estey, Elihu
O'Donoghue, Bernadette
Smith, B. Douglas
Bridges, John F. P.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (05) : 942 - 948

← 1 2 3 4 5 →